Clinical Trial Update: Phosphodiesterase Type 5 Inhibition With Tadalafil Changes Outcomes in Heart Failure: Extent of Renal Damage [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating tadalafil for heart failure and pulmonary hypertension has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Pulmonary Hypertension

Drugs mentioned

• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Heart Failure, Pulmonary Hypertension | Phase 3 | Status: WITHDRAWN